Trials / Completed
CompletedNCT03888911
Benefit and Tolerability of IQP-LU-104 in Weight Loss
Double-blind, Randomized, Three-armed, Placebo-controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-LU-104 in Reducing Body Weight in Overweight and Moderately Obese Subjects
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- InQpharm Group · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study is to evaluate the benefit and tolerability of two dosages of IQP-LU-104 (5120mg and 2560mg daily) in reducing body weight in overweight and moderately obese subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | High dose IQP-LU-104 (5120mg) | 1 sachet to be taken 2 times daily orally, together with 2 main meals |
| DIETARY_SUPPLEMENT | Low dose IQP-LU-104 (2560mg) | 1 sachet to be taken 2 times daily orally, together with 2 main meals |
| DIETARY_SUPPLEMENT | Placebo | 1 sachet to be taken 2 times daily orally, together with 2 main meals |
Timeline
- Start date
- 2019-03-05
- Primary completion
- 2019-11-21
- Completion
- 2019-11-21
- First posted
- 2019-03-25
- Last updated
- 2022-08-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03888911. Inclusion in this directory is not an endorsement.